Golimumab - Janssen Biotech

Drug Profile

Golimumab - Janssen Biotech

Alternative Names: Anti-TNF-alpha monoclonal antibody - Centocor/Medarex; CNTO-148; Shinponi; Shinponi® 50mg Autoinjector; Simponi; Simponi Aria; Simponi I.V; Sympony; Symposony; Xinpini

Latest Information Update: 20 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centocor; Medarex
  • Developer Centocor; Centocor Ortho Biotech; Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Merck & Co; Mitsubishi Tanabe Pharma Corporation
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase I/II Hearing disorders
  • Phase I Type 1 diabetes mellitus
  • Discontinued Asthma; Cardiovascular disorders; Sarcoidosis; Uveitis

Most Recent Events

  • 29 Oct 2018 Phase-III clinical trials in Ulcerative colitis (In adolescents, In children, Treatment-experienced) in USA (SC) (NCT03596645)
  • 07 Sep 2018 Janssen Research and Development plans the phase II VEGA trial in Ulcerative colitis (Combination therapy, Treatment-experienced, In adults, In the elderly) (SC) (NCT03662542)
  • 24 Jul 2018 Janssen Research & Development plans the phase III PURSUIT 2 trial for Ulcerative colitis (In children, In adolescents, Treatment-experienced) in the US, Belgium, Brazil, France, South Korea, Poland and Taiwan (NCT03596645) (EudraCT2017-004496-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top